Gilead Collaborates with Merus For Novel Antibody-Based Trispecific T-Cell Engagers

By Lalit Mishra

Pharma Deals Review: Vol 2024 Issue 3 (Table of Contents)

Published: 22 Mar-2024

DOI: 10.3833/pdr.v2024.i3.2861     ISSN: 1756-7874

Section: Research & Development



In order to strengthen its oncology portfolio, Gilead Sciences has entered into a research collaboration, option and license agreement with Merus to discover novel dual tumour-associated antigens (TAA)-targeting trispecific antibodies...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details